Recent advances in myelodysplasia: update from 2011 ASH annual meeting

Liu, Delong

doi:10.1186/1756-8722-5-s1-a4

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it would help to reduce treatment costs, because oral administration does not require a qualified team. Nevertheless, the oral bioavailability of decitabine described in the literature is very low, 3.9%-14%, 43 probably due to its low permeability (log P=−2.2) and its high hepatic metabolism limiting its half-life and oral administration.…”

mentioning

confidence: 99%

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia

Briot

Roger

Lautram

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia

Briot

Roger

Lautram

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…LDCs have shown hopeful results as delivery system for hydrophilic antitrypanosomal drugs [ 96 , 97 ], for oral application of methotrexate [ 94 ], and, more recently, for chemotherapy agents [ 1 , 95 ], such as decitabine, a drug that shows low oral bioavailability [ 98 ]. Neupane et al [ 99 ] developed LDC nanoparticles of decitabine to increase its permeability and protect against chemical degradation.…”

Section: Lipid Nanoparticles (Lnp)mentioning

confidence: 99%

Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives

Torrecilla

Rodríguez-Gascón

Solinís

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

The efforts made to develop RNAi-based therapies have led to productive research in the field of infections in humans, such as hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), human cytomegalovirus (HCMV), herpetic keratitis, human papillomavirus, or influenza virus. Naked RNAi molecules are rapidly digested by nucleases in the serum, and due to their negative surface charge, entry into the cell cytoplasm is also hampered, which makes necessary the use of delivery systems to exploit the full potential of RNAi therapeutics. Lipid nanoparticles (LNP) represent one of the most widely used delivery systems for in vivo application of RNAi due to their relative safety and simplicity of production, joint with the enhanced payload and protection of encapsulated RNAs. Moreover, LNP may be functionalized to reach target cells, and they may be used to combine RNAi molecules with conventional drug substances to reduce resistance or improve efficiency. This review features the current application of LNP in RNAi mediated therapy against viral infections and aims to explore possible future lines of action in this field.

show abstract

Lipid based nanocarrier system for the potential oral delivery of decitabine: Formulation design, characterization, ex vivo, and in vivo assessment

Neupane

Srivastava

Ahmad

et al. 2014

International Journal of Pharmaceutics

102

View full text Add to dashboard Cite

Recent advances in myelodysplasia: update from 2011 ASH annual meeting

Cited by 4 publications

References 16 publications

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia

Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives

Lipid based nanocarrier system for the potential oral delivery of decitabine: Formulation design, characterization, ex vivo, and in vivo assessment

Contact Info

Product

Resources

About